Lumana Invest

VIVOLTA specializes in the contract development and manufacturing of electrospun medical products, focusing on nanofiber-based solutions that aid the body's natural healing processes. The company has developed advanced electrospinning technologies that replicate the human extracellular matrix in a scalable and reproducible manner. This includes a range of methods such as melt electrospinning, wet electrospinning, and emulsion electrospinning. VIVOLTA’s innovations provide medical professionals with effective tools to enhance the production of medical implants and support a variety of medical applications, thereby improving the efficiency of electrospinning research.

ScoutinScience develops the SiS-AI platform, an advanced artificial intelligence technology designed to analyze scientific pre-publications and identify promising research with significant business potential. The company focuses on enhancing the impact of research by assisting technology transfer offices (TTOs) and R&D departments in discovering new technologies and improving their competitive edge. By automating the scouting process for high-tech transfer opportunities within scientific literature and data sources, ScoutinScience enables universities and research institutions to identify valuable partnership prospects and increase the flow of deals in the technology transfer pipeline. Ultimately, ScoutinScience aims to convert scientific advancements into innovative products and services that benefit society.

ATRO Medical B.V., based in Nijmegen, the Netherlands, specializes in the development of anatomically shaped polymer meniscus implants, specifically the Trammpolin. This innovative prosthesis is designed to replace damaged menisci, restoring their protective function by acting as a joint spacer and shock absorber. The Trammpolin mimics the natural meniscus, facilitating adequate load distribution within the knee joint, which can provide significant relief for osteoarthritis patients suffering from severe pain. ATRO Medical emerged as a spin-out from DSM and Radboudumc, leveraging expertise from a public-private collaboration initiated in 2010 that involved various universities, private companies, and support from the Dutch government. This collaborative effort has been instrumental in the design and development of the Trammpolin prototype.

Neuroplast is a biotechnology company that specializes in neuro-regenerative personalized medicine, focusing on the development of autologous stem cell products. The company aims to address critical medical conditions such as spinal cord injuries, amyotrophic lateral sclerosis, and traumatic brain injuries. By isolating, manufacturing, and reinserting patients' own cells, Neuroplast’s platform enhances the potential for successful treatment and aims to improve the quality of life for patients. The company is committed to establishing dedicated standards and regulations within the rapidly evolving field of regenerative medicine to ensure the efficacy and safety of its therapies.

Sencure is a Dutch start-up established in 2021 that specializes in the development of integrated circuit technology for next-generation healthcare wearable devices. By uniting medical device developers and integrated circuit designers, Sencure focuses on creating ultra-low-power biometric sensing chips capable of measuring electrophysiological parameters on the human body. These innovations facilitate a variety of wearable biometric services, enabling healthcare professionals to monitor stress, activity levels, and other vital health metrics in real-time. Sencure's technology is applicable across diverse sectors, including health monitoring devices, disposable medical patches, and health tracking solutions, making it a significant player in the wearable biosensor technology market for remote health monitoring, preventative care, clinical research, and overall wellness.

Eurekite BV, based in Enschede, the Netherlands, specializes in the manufacture of flexible ceramic materials. Established in May 2015 as a spin-off from the University of Twente, the company focuses on the development and commercialization of its innovative technology, known as Flexiramics®. This technology emerged from the Inorganic Materials Science Group of the MESA + Institute for Nanotechnology, led by Professor Andre ten Elshof. Eurekite combines expertise in formulation chemistry, production technology, and composite development, with its disruptive materials attracting investment from prominent venture capital firms.

VIVOLTA specializes in the contract development and manufacturing of electrospun medical products, focusing on nanofiber-based solutions that aid the body's natural healing processes. The company has developed advanced electrospinning technologies that replicate the human extracellular matrix in a scalable and reproducible manner. This includes a range of methods such as melt electrospinning, wet electrospinning, and emulsion electrospinning. VIVOLTA’s innovations provide medical professionals with effective tools to enhance the production of medical implants and support a variety of medical applications, thereby improving the efficiency of electrospinning research.

LipoCoat is a biotech company spun off from the University of Twente, specializing in innovative coating technology aimed at enhancing the safety and comfort of medical devices. The company has developed LipoCoat® coatings that are bio-inspired, hydrophilic, anti-fouling, multi-purpose, and sustainable, suitable for various applications including contact lenses, catheters, and implants. This technology effectively makes biomaterial surfaces non-thrombogenic and resistant to microbial and protein contamination, thereby improving the overall performance of medical devices. LipoCoat has gained recognition for its contributions to the field, having won numerous awards, competitions, and grants over the past three years.

Neuroplast is a biotechnology company that specializes in neuro-regenerative personalized medicine, focusing on the development of autologous stem cell products. The company aims to address critical medical conditions such as spinal cord injuries, amyotrophic lateral sclerosis, and traumatic brain injuries. By isolating, manufacturing, and reinserting patients' own cells, Neuroplast’s platform enhances the potential for successful treatment and aims to improve the quality of life for patients. The company is committed to establishing dedicated standards and regulations within the rapidly evolving field of regenerative medicine to ensure the efficacy and safety of its therapies.